Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload

Am J Physiol Heart Circ Physiol. 2018 Sep 1;315(3):H463-H473. doi: 10.1152/ajpheart.00086.2018. Epub 2018 May 18.

Abstract

The cardiac extracellular matrix is a complex architectural network that serves many functions, including providing structural and biochemical support to surrounding cells and regulating intercellular signaling pathways. Cardiac function is directly affected by extracellular matrix (ECM) composition, and alterations of the ECM contribute to the progression of heart failure. Initially, collagen deposition is an adaptive response that aims to preserve tissue integrity and maintain normal ventricular function. However, the synergistic effects of proinflammatory and profibrotic responses induce a vicious cycle, which causes excess activation of myofibroblasts, significantly increasing collagen deposition and accumulation in the matrix. Furthermore, excess synthesis and activation of the enzyme lysyl oxidase (LOX) during disease increases collagen cross-linking, which significantly increases collagen resistance to degradation by matrix metalloproteinases (MMPs). In the present study, the aortocaval fistula model of volume overload (VO) was used to determine whether LOX inhibition could prevent adverse changes in the ECM and subsequent cardiac dysfunction. The major findings from this study were that LOX inhibition 1) prevented VO-induced increases in left ventricular wall stress; 2) partially attenuated VO-induced ventricular hypertrophy; 3) completely blocked the increases in fibrotic proteins, including collagens, MMPs, and their tissue inhibitors; and 4) prevented the VO-induced decline in cardiac function. It remains unclear whether a direct interaction between LOX and MMPs exists; however, our experiments suggest a potential link between the two because LOX inhibition completely attenuated VO-induced increases in MMPs. Overall, our study demonstrated key cardioprotective effects of LOX inhibition against adverse cardiac remodeling due to chronic VO. NEW & NOTEWORTHY Although the primary role of lysyl oxidase (LOX) is to cross-link collagens, we found that elevated LOX during cardiac disease plays a key role in the progression of heart failure. Here, we show that inhibition of LOX in volume-overloaded rats prevented the development of cardiac dysfunction and improved ventricular collagen and matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles.

Keywords: cross link; extracellular matrix; fibrosis; heart failure; ventricular.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopropionitrile / pharmacology
  • Aminopropionitrile / therapeutic use
  • Animals
  • Arteriovenous Fistula / complications
  • Collagen / metabolism
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Extracellular Matrix / drug effects*
  • Extracellular Matrix / metabolism
  • Hypertrophy, Left Ventricular / drug therapy*
  • Hypertrophy, Left Ventricular / etiology
  • Male
  • Matrix Metalloproteinases / metabolism
  • Myocardium / metabolism*
  • Protein-Lysine 6-Oxidase / antagonists & inhibitors*
  • Protein-Lysine 6-Oxidase / metabolism
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Enzyme Inhibitors
  • Aminopropionitrile
  • Collagen
  • Protein-Lysine 6-Oxidase
  • Matrix Metalloproteinases